Alector licenses brain-penetrant GCase therapy to Genentech in deal worth up to $1.27bn

What's the deal? On 5 October 2026 Alector entered a global licence agreement with Genentech, a member of the Roche Group, covering Alector's brain-penetrant GCase (glucocerebrosidase) enzyme replacement therapy candidate for Parkinson's disease and other neurodegenerative diseases. Alector will receive a $100m upfront payment and is eligible for up to $1.17bn in development, regulatory and commercial milestone payments, plus tiered royalties on net sales.

Why it matters: GCase deficiency is linked to the accumulation of damaged lysosomal proteins implicated in Parkinson's disease, particularly in people carrying GBA1 mutations. The asset is at a preclinical stage but is designed to cross the blood-brain barrier — a significant validation of Alector's neuroscience approach in a field with few disease-modifying therapies, and Genentech's latest external licensing move in neurodegeneration.

Read more: GlobeNewswire, 5 October 2026